Companies: 10,795·Total market cap: $144.5T
Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

ARTVNASDAQHealthcare● Active
$6.80
$-0.05(-0.73%)
Market Cap$168073376
P/E Ratio
52W High$14.53
52W Low$1.47

Artiva Biotherapeutics, Inc. (ARTV) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

artv · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Artiva Biotherapeutics, Inc. (ARTV) measures how much investors pay for each dollar of the company's trailing earnings. ARTV's current PE ratio of N/A is calculated by dividing its stock price of $6.80 by its TTM earnings per share of -$3.53.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-2.91
Based on 4 analysts
EPS (TTM)
-$3.53
TTM · diluted EPS
PEG Ratio
0.18
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Artiva Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.You
ARTV
$168MN/A-$3.53
Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc.
ADVM
$96MN/A-$6.62
ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc.
ALXO
$211MN/A-$1.90
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited
CNTB
$139MN/A-$1.00
Precision BioSciences, Inc.
Precision BioSciences, Inc.
DTIL
$87MN/A-$3.63
Fractyl Health, Inc. Common Stock
Fractyl Health, Inc. Common Stock
GUTS
$48MN/A-$1.86
InflaRx N.V.
InflaRx N.V.
IFRX
$124MN/A-$0.68

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-3.43
2024-12-31
FY2024
$-2.40
2023-12-31
FY2023
$-1.19
2022-12-31
FY2022
$-3.32
2021-12-31
FY2021
$-4.08
2020-12-31
FY2020
$-1.02
2019-12-31
FY2019
$0.00

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Artiva Biotherapeutics, Inc. (ARTV) measures how much investors pay for each dollar of the company's trailing earnings. ARTV's current PE ratio of N/A is calculated by dividing its stock price of $6.80 by its TTM earnings per share of -$3.53.

PE Ratio = Stock Price ÷ EPS (TTM)
= $6.80 ÷ -$3.53 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

ARTV pe ratio · 6 questions

ARTV's current PE ratio is N/A as of 2026-06-09, based on a stock price of $6.80 and TTM EPS of -$3.53. Data sourced from Financial Modeling Prep via ARTV's SEC 10-K and 10-Q filings.

ARTV PE ratioWhat is ARTV PE ratioCurrent PE ratio of ARTVARTV PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Artiva Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09